NCT07246863 2026-03-04
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
CatalYm GmbH
Compugen Ltd
Grifols Therapeutics LLC
Glonova Pharma Co., Ltd
Hope Biosciences Research Foundation
Medigen Biotechnology Corporation